| Back to Homepage |
Case 42 - Discussion |
Uploaded: 2008-01-18, Updated: 2008-01-18 |
|
MICROSCOPIC EXAM |
|||||||||||||||||||||||
|
PERIPHERAL BLOOD
WBC 7.67 x 10^3/ul; RBC 2.75 x10^6/uL; Hgb 8.5 g/dl; Hct 25%; MCV
90.9 fl; RDW 15.7; Plt 39 x10^3/ul.
BONE MARROW CORE BIOPSY AND CLOT SECTION:
Quality: Adequate.
BONE MARROW ASPIRATE SMEAR AND TOUCH IMPRINTS:
Quality: Adequate, hypercellular with spicules.
|
|||||||||||||||||||||||
|
FLOW CYTOMETRY INTERPRETATION |
|||||||||||||||||||||||
|
There are two aberrant populations of cells identified on flow cytometry. The first aberrant population of cells express dim CD45, CD38, CD138, CD8, dim partial cytoplasmic CD79a, and surface and cytoplasmic monotypic light chain kappa, which account for 27% of the total events analyzed. The second population account for 10% of the total events analyzed and express CD19, CD5, CD23 and monotypic surface kappa light chain. The immunophenotype for the second population is consistent with B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. The immunophenotype of the first population of cells is consistent with large cell lymphoma of B-cell lineage with plasmablastic differentiation.
H gate Dim CD45+ A gate Bright CD45+ Total events events = 18579 events = 7245 analyzed = 78464 (27% of total) (10% of total) CD45+/CD14- 100% 99% CD14+ <2% Total CD13+ 2% CD13+/CD34+ <2% Total CD15+ <2% CD15+/CD34+ <2% Total CD33+ <2% CD33+/CD34+ <2% Total CD34+ <2% Total HLA DR+ 7% HLA-DR+/CD34+ <2% Total CD117+ 7% CD117+/CD34+ <2% CD19+/CD3- <2% 62% CD3+/CD19- <2% 20% CD19+CD20+ <2% <2% Total CD38+ 98% 28% CD19+/CD38+ <2% 3% CD19+/CD10+ <2% <2% CD5+/CD19+ <2% 70% CD5+/CD19- <2% 5% CD19+/CD23+ <2% 60% CD19+/FMC7+ <2% <2% Total CD26+ 2% 5% CD2+/CD7+ <2% 15% CD3+/CD5+ 5% 16% CD3+/CD4+ <2% 9% Total CD8+ 87% 11% CD3+/CD8+ 14% 4% Total CD16+ 2% 7% CD3-/CD56+ <2% 7% sIg Kappa+ 100% 80% sIg Lambda+ <2% <2% cCD3+ <2% cCD79a+ 34% cCD19+ <2% cMPO+ 31% cTdT+ 4%
Gated on CD19+ cells
CD19+/sIg Kappa+ 96%
CD19+/sIg Lambda+ 2%
A gate Bright Total events CD38+/CD138+ events = analyzed = 42112 9355 (22% of total) CD45+/CD38+ 94% CD38+/CD19+ <2% CD38+/CD117+ <2%
Gated on CD138+ cells
CD138+/cIg Kappa+ 56%
CD138+/cIg Lambda+ <2%
|
|||||||||||||||||||||||
|
IMMUNOHISTOCHEMISTRY STAINS |
|||||||||||||||||||||||
|
|||||||||||||||||||||||
|
IN SITU HYBRIDIZATION |
|||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
| CYTOGENETICS (UNMC, Cytogenetics) | |||||||||||||||||||||||
|
Cytogenetic analysis revealed the presence of an abnormal
hypertriploid clone characterized by the gain of chromosomes S, Y,
1, 7, 12, 13, 19, 22; loss of chromosomes 4 and 6; interstitial
deletions of 1p and 5q; additional material of unknown origin on
11p; reciprocal translocations involving 8q and 14q, and 12q and
14q; four derivative chromosomes resulting from unbalanced
translocations involving 12q and 14q and a complex rearrangement of
8q, 14q and 21p; and this presence of two marker chromosomes. One
abnormal cell characterized by t(12;14) represents the primary
clone. | |||||||||||||||||||||||
|
DIAGNOSIS |
|||||||||||||||||||||||
|
|
|
||||||||||||||||||||||